Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:immunotherapy
|
| gptkbp:administered_by |
oral tablet
inhalation solution |
| gptkbp:approves |
gptkb:1971
gptkb:FDA |
| gptkbp:brand |
gptkb:Copegus
gptkb:Rebetol Virazole |
| gptkbp:casnumber |
36791-04-5
|
| gptkbp:chemical_formula |
C8 H11 N5 O5
|
| gptkbp:class |
nucleoside analog
|
| gptkbp:clinical_trial |
HCV treatment studies
RSV treatment studies |
| gptkbp:composed_by |
can be produced from ribose
synthesized from guanosine |
| gptkbp:contraindication |
pregnancy
severe renal impairment |
| gptkbp:developed_by |
ICN Pharmaceuticals
|
| gptkbp:drug_interactions |
gptkb:Interpol
gptkb:didanosine gptkb:zidovudine |
| gptkbp:formulation |
injection
oral capsule |
| https://www.w3.org/2000/01/rdf-schema#label |
Ribavirin
|
| gptkbp:marketed_as |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:mechanism_of_action |
inhibits viral RNA synthesis
|
| gptkbp:pharmacokinetics |
excreted in urine
oral bioavailability 45% to 65% half Life 1.5 hours |
| gptkbp:research |
potential use in COVID-19
studies on Crimean-Congo hemorrhagic fever studies on Ebola virus studies on Lassa fever studies on viral hemorrhagic fevers |
| gptkbp:side_effect |
gptkb:anemia
gptkb:depression fatigue headache nausea rash insomnia thrombocytopenia |
| gptkbp:targets |
RNA viruses
|
| gptkbp:used_for |
treatment of hepatitis C
treatment of respiratory syncytial virus (RSV) infection |
| gptkbp:bfsParent |
gptkb:virus
|
| gptkbp:bfsLayer |
4
|